Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system

被引:53
作者
Custodio, Melani R. [1 ]
Koike, Marcia K. [2 ]
Neves, Katia R. [1 ]
dos Reis, Luciene M. [1 ]
Graciolli, Fabiana G. [1 ]
Neves, Carolina L. [1 ]
Batista, Daniella G. [1 ]
Magalhaes, Andrea O. [1 ]
Hawlitschek, Philippe [1 ]
Oliveira, Ivone B. [1 ]
Dominguez, Wagner V. [1 ]
Moyses, Rosa M. A. [1 ]
Jorgetti, Vanda [1 ]
机构
[1] Univ Sao Paulo, Dept Internal Med, Div Nephrol, Sao Paulo, Brazil
[2] Univ Sao Paulo, Lab Emergency Med, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
FGF-23; hyperphosphatemia; left ventricular hypertrophy; parathyroid hormone; vascular calcification; LEFT-VENTRICULAR HYPERTROPHY; CHRONIC KIDNEY-DISEASE; FIBROBLAST-GROWTH-FACTOR; STAGE RENAL-DISEASE; VASCULAR CALCIFICATION; HEMODIALYSIS-PATIENTS; INORGANIC-PHOSPHATE; MINERAL METABOLISM; DIALYSIS PATIENTS; BLOOD-PRESSURE;
D O I
10.1093/ndt/gfr447
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Cardiac remodeling in uremia is characterized by left ventricular hypertrophy, interstitial fibrosis and microvascular disease. Cardiovascular disease is the leading cause of death in uremic patients, but coronary events alone are not the prevalent cause, sudden death and heart failure are. We studied the cardiac remodeling in experimental uremia, evaluating the isolated effect of parathyroid hormone (PTH) and phosphorus. Methods. Wistar rats were submitted to parathyroidectomy (PTx) and 5/6 nephrectomy (Nx); they also received vehicle (V) and PTH at normal (nPTH) or high (hPTH) doses. They were fed with a poor-phosphorus (pP) or rich-phosphorus (rP) diet and were divided into the following groups: 'Sham': G1 (V + normal-phosphorus diet (np)) and 'Nx + PTx': G2 (nPTH + pP), G3 (nPTH + rP), G4 (hPTH + pP) and G5 (hPTH + rP). After 8 weeks, biochemical analysis, myocardium morphometry and arteriolar morphological analysis were performed. In addition, using immunohistochemical analysis, we evaluated angiotensin II, alpha-actin, transforming growth factor-beta (TGF-beta) and nitrotyrosine, as well as fibroblast growth factor-23 (FGF-23), fibroblast growth factor receptor-1 (FGFR-1) and runt-related transcription factor-2 (Runx-2) expression. Results. Nx animals presented higher serum creatinine levels as well as arterial hypertension. Higher PTH levels were associated with myocardial hypertrophy and fibrosis as well as a higher coronary lesion score. High PTH animals also presented a higher myocardial expression of TGF-beta, angiotensin II, FGF-23 and nitrotyrosine and a lower expression of alpha-actin. Phosphorus overload was associated with higher serum FGF-23 levels and Runx-2, as well as myocardial hypertrophy. FGFR-1 was positive in the cardiomyocytes of all groups as well as in calcified coronaries of G4 and G5 whereas Runx-2 was positive in G3, G4 and G5. Conclusion. In uremia, PTH and phosphorus overload are both independently associated with major changes related to the cardiac remodeling process, emphasizing the need for a better control of these factors in chronic kidney disease.
引用
收藏
页码:1437 / 1445
页数:9
相关论文
共 34 条
[1]   Left ventricular hypertrophy: Is hyperphosphatemia among dialysis patients a risk factor? [J].
Achinger, Steven G. ;
Ayus, Juan Carlos .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 :S255-S261
[2]  
AMANN K, 1995, NEPHROL DIAL TRANSPL, V10, P2043
[3]   Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia [J].
Amann, K ;
Törnig, J ;
Kugel, B ;
Gross, ML ;
Tyralla, K ;
El-Shakmak, A ;
Szabo, A ;
Ritz, E .
KIDNEY INTERNATIONAL, 2003, 63 (04) :1296-1301
[4]  
[Anonymous], 2006, USRDS 2006 ANN DAT R
[5]   Inorganic phosphate regulates multiple genes during osteoblast differentiation, including Nrf2 [J].
Beck, GR ;
Moran, E ;
Knecht, N .
EXPERIMENTAL CELL RESEARCH, 2003, 288 (02) :288-300
[6]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[7]  
BOGIN E, 1981, J CLIN INVEST, V67, P1215, DOI 10.1172/JCI110137
[8]   Fibroblast Growth Factor 23 in Chronic Kidney Disease: Bridging the Gap between Bone Mineral Metabolism and Left Ventricular Hypertrophy [J].
Canziani, M. E. F. ;
Tomiyama, C. ;
Higa, A. ;
Draibe, S. A. ;
Carvalho, A. B. .
BLOOD PURIFICATION, 2011, 31 (1-3) :26-32
[9]   Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling [J].
Cohn, JN ;
Ferrari, R ;
Sharpe, N .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (03) :569-582
[10]   Biological activities of fibroblast growth factor-2 in the adult myocardium [J].
Detillieux, KA ;
Sheikh, F ;
Kardami, E ;
Cattini, PA .
CARDIOVASCULAR RESEARCH, 2003, 57 (01) :8-19